Navigation Links
New Diagnostic Biomarker Test Shows Promise in Monitoring Ovarian Cancer
Date:7/22/2009

CHICAGO, July 22 /PRNewswire-FirstCall/ -- Ovarian malignancies are a leading cause of cancer death in women because they are usually detected in the late stages when the disease is incurable. Encouraging new research presented by Abbott today at the American Association for Clinical Chemistry annual meeting shows that a novel diagnostic marker, human epididymal protein 4 or HE4, combined with other tests, can be used to more effectively monitor for early-stage ovarian cancer (EOC), improving treatment options for many of the 22,000 women in the United States who develop this deadly disease each year.

New research on HE4 presented today by Richard Moore, M.D., associate professor in the Program for Women's Oncology at Women and Infants' Hospital/Brown University, at a scientific workshop hosted by Abbott, provides important validation for the use of the HE4 test in combination with CA125, the current standard for monitoring ovarian cancer, in estimating EOC risk in women presenting with pelvic masses. The HE4 test was developed through research efforts aimed at identifying combinations of biomarkers to add sensitivity to the CA125 test, which is limited in its sensitivity and specificity, as well as its ability to monitor early stage epithelial ovarian cancer (EOC).

"Our results show that the dual marker combination of HE4 and CA125 can aid in the differentiation of benign pelvic masses from ovarian malignancies in women diagnosed with a pelvic mass," said Moore. "This is exciting as it will help us improve the care we give to the many women who are afflicted by this deadly disease."

"More than 250,000 women present to their physician each year with a suspicious pelvic mass, yet there is still no reliable tool to differentiate malignant disease from other benign gynecologic conditions, making early detection a significant challenge," said Robert Doss, Ph.D., divisional vice president, research and development, Abbott Diagnostics. "HE4 represents an important advancement in monitoring these pelvic masses."

Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop this new ovarian cancer marker for use on Abbott's automated ARCHITECT(R) diagnostic analyzers. A manual form of the HE4 test has been approved by the Food and Drug Association (FDA) as an aid in monitoring recurrence or progressive disease in patients with EOC and is CE marked for use within the European Union as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women.

About Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer death in women. An estimated one in 72 women will develop ovarian cancer in their lifetimes. It accounts for 31 percent of cancers of the female genital organs. Women who are postmenopausal are at the greatest risk for ovarian cancer.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
10. New peritoneal dialysis diagnostic discovered
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
(Date:6/24/2016)... ... 24, 2016 , ... To succeed under value-based payments, healthcare ... unsure how to move forward, given the need to sustain current operations. PYA ... to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology: